

Deficient DNA Damage Signaling Leads to Chemoresistance to Cisplatin in Oral Cancer

Ling Wang, Adam J. Mosel, Gregory G. Oakley, and Aimin Peng

Abstract

Activation of the cellular DNA damage response (DDR) is an important determinant of cell sensitivity to cisplatin and other chemotherapeutic drugs that eliminate tumor cells through induction of DNA damage. It is therefore important to investigate whether alterations of the DNA damage-signaling pathway confer chemoresistance in cancer cells and whether pharmacologic manipulation of the DDR pathway can resensitize these cells to cancer therapy. In a panel of oral/laryngeal squamous cell carcinoma (SCC) cell lines, we observed deficiencies in DNA damage signaling in correlation with cisplatin resistance, but not with DNA repair. These deficiencies are consistent with reduced expression of components of the ataxia telangiectasia mutated (ATM)-dependent signaling pathway and, in particular, strong upregulation of Wip1, a negative regulator of the ATM pathway. Wip1 knockdown or inhibition enhanced DNA damage signaling and resensitized oral SCC cells to cisplatin. In contrast to the previously reported involvement of Wip1 in cancer, Wip1 upregulation and function in these SCC cells is independent of p53. Finally, using xenograft tumor models, we showed that Wip1 upregulation promotes tumorigenesis and its inhibition improves the tumor response to cisplatin. Thus, this study reveals that chemoresistance in oral SCCs is partially attributed to deficiencies in DNA damage signaling, and Wip1 is an effective drug target for enhanced cancer therapy. *Mol Cancer Ther*; 11(11); 2401–9. ©2012 AACR.

Introduction

Radiation and most chemotherapeutic drugs exert their toxicity to tumor cells primarily through induction of DNA damage, which halts cell proliferation and induces cell death. One such genotoxic drug commonly used for chemotherapy is cisplatin, or *cis*-diamminedichloroplatinum(II). Cisplatin was first approved by the U.S. Food and Drug Administration (FDA) in 1978 for the use in testicular and ovarian cancers. Over decades, cisplatin and other platinum-based analogs have become important weapons battling against a wide variety of cancers, including testicular, breast, ovarian, lung, and oral cancers. Cisplatin delivers initial success with partial responses and disease stabilization in many patients, but unfortunately, its clinical usefulness is ultimately limited by the fact that a majority of cancer patients will eventually develop resistance to cisplatin, leading to tumor recurrence (1, 2). Upon cellular absorption and processing, cisplatin binds DNA and causes DNA strand cross-linking. This form of DNA lesion is then sensed by a

cellular surveillance mechanism, generally termed "the DNA damage response (DDR)," which ultimately determines cell fate through coordinated activation of various downstream pathways. It has been therefore widely anticipated that future delineation of the DDR pathway holds a key to better understanding of chemoresistance and development of more efficacious cancer treatments (3).

As a conserved mechanism evolved by eukaryotic cells to govern genomic integrity, the DDR encompasses various lesion-specific DNA repair pathways and a sophisticated signaling network. DNA damage signaling subsequently activates either the DNA damage checkpoint to arrest cell-cycle progression, or apoptosis to eliminate the damaged cell. At the center of DNA damage signaling are the phosphoinositide 3-kinase-related kinases (PIKK), ATM and ATR. Activation of ATM and Rad3-related (ATR) by DNA damage in turn results in phosphorylation of dozens of physiologic substrates that control various pathways of DNA repair, checkpoint control, apoptosis, and transcription (4). For example, ATM and ATR activate the checkpoint kinases, Chk1 and Chk2, which then phosphorylate and inactivate Cdc25, a regulator of cyclin-dependent kinases (Cdk) required for Cdk activation and cell-cycle progression. Moreover, ATM and ATR phosphorylate a histone H2A variant, H2AX, at the site of DNA damage. Phosphorylated H2AX (γ -H2AX) then recruits a number of DDR factors onto damaged chromatin to facilitate DNA repair and checkpoint signaling. Despite functional similarities, ATM and ATR are activated through distinct mechanisms. ATM activation is promoted by the

Authors' Affiliation: Department of Oral Biology, College of Dentistry, University of Nebraska Medical Center, Lincoln, Nebraska

Corresponding Author: Aimin Peng, Department of Oral Biology, College of Dentistry, University of Nebraska Medical Center, Lincoln, NE 68583. Phone: 402-472-5903; Fax: 402-472-2551; E-mail: Aimin.Peng@UNMC.edu

doi: 10.1158/1535-7163.MCT-12-0448

©2012 American Association for Cancer Research.

heterotrimeric complex Mre11/Rad50/Nbs1 that may directly recognize DNA double-strand breaks (5, 6), whereas ATR is activated through binding to replication protein A-coated ssDNA and TopBP1 (7, 8). Both ATM and ATR have been implicated in the cellular response to cisplatin (9–11).

As DDR signaling relies largely on kinase cascades and protein phosphorylation, it is not surprising that recent studies started to reveal important involvement of Ser/Thr phosphatases in this pathway (12). One of the best-studied examples is the wild-type p53-induced phosphatase 1 (Wip1). It has been shown that expression of Wip1 is induced after DNA damage in a p53-dependent manner. Upon induction, Wip1 functions as a homeostatic regulator of the DDR by dephosphorylating multiple S/TQ sites of ATM, Chk1, Chk2, p53, γ -H2AX that are targeted by ATM/ATR. Wip1-dependent dephosphorylation leads to deactivation of these DDR factors, thus allowing cells to turn off the DDR signaling pathway and resume cell proliferation (reviewed in refs. 12, 13). Interestingly, Wip1 has been shown to be amplified or overexpressed in a number of human cancers, including breast cancer, neuroblastoma, and ovarian cancer. The oncogenic role of Wip1 has been well demonstrated both *in vitro* and *in vivo*, particularly for breast cancer. Overexpression of Wip1 promotes cell growth and transformation induced by Ras or other oncogenes, whereas Wip1 depletion suppresses mammary tumorigenesis (reviewed in refs. 13, 14).

The ultimate outcome of the DDR could be either cell survival or death—if the cell successfully repairs DNA damage, it would turn off the DDR and return to cell proliferation, whereas failure of DNA repair leads to programmed cell death. Under normal circumstances, such a well-balanced mechanism ensures genomic integrity, yet at the same time, avoids excessive cell loss. However, in tumor cells treated with radiotherapy or chemotherapy, DNA repair and cell survival attenuate the killing effect of the treatment and lead to undesired therapeutic outcomes. Cisplatin-induced DNA damage is repaired by nucleotide-excision repair (NER) and other repair pathways, and upregulation of genes involved in these pathways, including ERCC1, POLH, BRCA1, and BRCA2, has been shown to render tumor cells resistant to cisplatin treatment (1).

Notably, the relationship between the DNA damage checkpoint pathway and tumor resistance to cisplatin is less understood, and perhaps also more complicated in nature. On one hand, checkpoint activation allows time for DNA repair and may thereby contribute to cell survival, but on the other hand, the same signaling pathway may induce cell death or senescence to confer a better treatment outcome. In this study, we sought to investigate the potential connection between the DDR signaling pathway and cisplatin response in a panel of well-characterized oral/laryngeal squamous cell carcinoma (SCC) cell lines (15). We observed deficient DNA damage signaling in some SCC cell lines, resulting from both reduced

expression of genes in the ATM-dependent checkpoint pathway, and upregulation of Wip1, the negative regulator of DNA damage signaling. The deficiency in DNA damage signaling is correlated with chemoresistance to cisplatin, but not with DNA repair. Importantly, knock-down or inhibition of Wip1 resensitizes the cisplatin-resistant cells *in vitro* and *in vivo*, suggesting exciting opportunities for combinatorial therapy.

Materials and Methods

Cell culture

Human oral/laryngeal SCC cell lines were obtained from Dr. Thomas Carey (University of Michigan, Ann Arbor, MI) in 2010 and 2011. These cell lines were previously characterized genetically and morphologically (15, 16), and have not been retested and authenticated in the present study. Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM, Sigma) supplemented with 10% FBS (Sigma). To measure cell sensitivity to cisplatin, cells were treated with cisplatin at indicated concentrations, and incubated for 1 to 4 days. The numbers of viable cells were counted using a hemocytometer. Lentiviral vectors expressing control nontargeting or Wip1 short hairpin RNAs (shRNA) were purchased from Sigma and used to infect cells following the protocol recommended by the manufacturer.

Immunoblotting

Immunoblotting was conducted as described previously (17, 18). Anti-ATM, Mre11, H2AX, γ -H2AX, Chk1, phospho-Chk2, phospho-ATR (Ser-428), p53 antibodies were purchased from Cell Signaling; anti- β -actin antibody was obtained from Abcam; anti-Smc1, Wip1, and phospho-Smc1 antibodies were purchased from Bethyl. The intensity of band signals was measured using NIH Image-J software.

Comet assay

A modified comet assay was conducted to measure DNA cross-link induced by cisplatin (19). Exponentially growing cells were treated with 16.7 μ mol/L cisplatin in DMEM medium for 2 hours at 37°C. Cells were washed with PBS buffer and the medium replaced with fresh DMEM and incubated for 24 hours to allow repair. Cells were treated with H₂O₂ (250 μ mol/L) for 15 minutes before collection to expose DNA cross-links. Cells were then trypsinized, washed, and plated in 0.65% low melting agarose. The agarose was allowed to solidify, and slides were incubated in lysis solution (2.5 mol/L NaCl, 100 mmol/L EDTA, 10 mmol/L Trizma base, pH 10.0) containing 1% Triton X-100 at 4°C for 2 hours. Slides were then washed with ice-cold water, and transferred to an electrophoresis tank containing room temperature alkaline solution (50 mmol/L NaOH, 1 mmol/L disodium EDTA, pH > 12.3) for 30 minutes incubation. Electrophoresis was carried out for 10 minutes at 1 V/cm. The slides were removed and incubated in neutralizing solution (0.4 mol/L Tris-HCl, pH 7.5) for 10 minutes.

Slides were stained with propidium iodide (25 $\mu\text{g}/\text{mL}$) and washed 5 minutes in ice-cold water to remove excess stain. Images were captured at $\times 10$ magnification using a Carl Zeiss Axiovert 40 CFL inverted microscope equipped with a mercury lamp. Fifty cells per sample were analyzed for the level of DNA cross-link by comparing the tail moment of the cisplatin/ H_2O_2 -treated cells to the untreated samples. Percentage decrease in tail moment (%DTM) was calculated with the formula $\%DTM = \left(1 - \frac{[TM_{dh} - TM_c]}{[TM_h - TM_c]}\right) \times 100$, where TM_c is the mean tail moment of the untreated control, TM_h is the mean tail moment of the H_2O_2 control (representing no cross-link), and TM_{dh} is the mean tail moment of the drug/ H_2O_2 -treated sample.

Xenograft tumor model

Athymic nude mice were purchased from NIH and housed at the animal facility at the UNMC College of Dentistry. SCC cells were implanted into 6-week-old female mice by a single subcutaneous injection of tumor cells ($2 - 6 \times 10^5$ cells in 100 μL of sterile PBS). The growth rates of tumors were determined by daily monitoring of tumor volume with vernier calipers [tumor volume = $1/2$ (length \times width 2)]. Upon completion of the study, the mice were euthanized, and their tumors were removed and weighed immediately. To test how tumors respond to chemotherapy, once the tumor size reached 50 mm^3 , cisplatin (5 mg/kg mouse), arsenic trioxide (10 mg/kg), and CCT007093 (2 mg/kg) were administered intraperitoneally every day for 5 days. Tumor size was monitored daily. Ten days after the initial treatment, the mice were euthanized, and tumors were removed and weighed. The volume of the tumor was compared among all experimental groups. Data were analyzed using an unpaired 2-tailed Student *t* test to determine the statistical significance.

Results

Altered DNA damage signaling in oral SCC cells

Activation of the DDR by cisplatin and other chemotherapeutic drugs involves complex signaling pathways composed of numerous proteins, such as ATM, Mre11, Chk1, and Smc1. We compared gene expression of multiple DDR factors in a panel of oral SCC cell lines in comparison to a nontumorigenic control keratinocyte cell line HaCaT, and observed reduced expression of ATM, Mre11, and H2AX in UM-SCC-11B and -38 cells (Fig. 1A). In comparison, other DDR factors, including Chk1, Smc1, and ATR, are expressed to comparable levels in all cell lines (Fig. 1A). We further examined the expression of a negative regulator of the DNA damage checkpoint, Wip1, which has been shown to dephosphorylate and deactivate ATM, H2AX, and other DDR factors. As shown in Fig. 1B, we detected strong upregulation of Wip1 in UM-SCC-11B and -38 cells. Consistent with the reduced expression of ATM, Mre11, H2AX, and enhanced expression of Wip1, activation of DNA damage signaling in UM-SCC-11B and




Figure 1. Deficient DNA damage signaling in oral cancer cells. A and B, a panel of oral/laryngeal SCC cell lines and a control nontumorigenic HaCaT cell line were maintained as described in Materials and Methods. These cells were examined by immunoblotting and compared for expression of ATM, Mre11, H2AX, Chk1, Smc1, and ATR (A), Wip1 and β -Actin (B). The intensity of band signals was measured using ImageJ software and normalized to β -actin. C, HaCaT and SCC cells were treated with cisplatin (16.7 $\mu\text{mol}/\text{L}$) for 4 hours and harvested for immunoblotting using phospho-Smc1, ATM, ATR, and γ -H2AX antibodies.

-38 cells is significantly impaired in response to cisplatin, as judged by reduced phosphorylation of Smc1, H2AX, and ATM (Fig. 1C). In contrast, ATR is efficiently phosphorylated in SCC-11B and -38 cells (Fig. 1C).

Deficient DDR correlates with cisplatin resistance but not with DNA repair

Interestingly, UM-SCC-11B and -38 cells that harbor impaired DDR signaling are more resistant to cisplatin. As shown in Fig. 2A and B, HaCaT and oral SCC cells exhibit varying sensitivities to cisplatin. UM-SCC-23 and -81B cells are generally as sensitive to cisplatin as the control HaCaT cells; UM-SCC-1 and -10B cells are considerably more resistant than HaCaT cells; whereas UM-SCC-11B and -38 cells are the most resistant to cisplatin. We then sought to determine the capacity of DNA repair in UM-SCC-11B and -38 cells. As shown in previous studies, DNA strand cross-link induced by cisplatin can be




Figure 2. Cisplatin resistance and DNA repair capacity in oral cancer cells. A, SCC and HaCaT cells were incubated with cisplatin at various concentrations for 4 days. Cell viability was determined as described in Materials and Methods and normalized to that without cisplatin treatment. The concentration of cisplatin that inhibits 50% cell growth (IC₅₀) was calculated for each cell line. B, SCC and HaCaT cells were incubated with cisplatin at 3.3 μmol/L and incubated for 1 to 4 days. Cell viability was determined and normalized to that of the first day. C, HaCaT, UM-SCC-11B, and UM-SCC-38 cells were treated with cisplatin (16.7 μmol/L) for 2 hours to induce DNA cross-link and then incubated for 24 hours for repair. The DNA repair capacity in these cells was assessed using a modified comet assay as described in Materials and Methods. Representative images of the comet assay are shown. The graph is based on 3 independent experiments with at least 50 cells per sample in each experiment.

measured using the comet assay (19). Surprisingly, no repair deficiency was found in UM-SCC-11B and -38 cells when compared with the control HaCaT cell (Fig. 2C).

p53-independent upregulation of Wip1

It has been shown that expression of Wip1 is induced by wild-type p53 after DNA damage (20). However, despite that previous studies discovered homozygous mutations of p53 in UM-SCC-11B and -38 cells (21), we observed

strong upregulation of Wip1 in these cells (Fig. 1B). Upon further examination of p53 status in UM-SCC-11B and -38 cells, we found that no p53 expression can be detected with or without cisplatin treatment (Fig. 3). Thus, the constitutive expression of Wip1 in these cells indicates Wip1 upregulation in a p53- and DNA damage-independent manner.

Wip1 suppression sensitizes UM-SCC-11B cells to cisplatin

To investigate whether Wip1 upregulation contributes to chemoresistance in UM-SCC-11B cells through DDR regulation, we sought to knockdown Wip1 expression using 2 lentiviral shRNA vectors. Both shRNA vectors partially reduced the level of Wip1 expression, and consequently, enhanced DDR signaling, as measured by Smc1 phosphorylation in response to cisplatin (Fig. 4A). Importantly, cell viability after cisplatin treatment was significantly reduced by Wip1 knockdown, indicating that chemoresistance in these cells is partially caused by Wip1 overexpression (Fig. 4B).

Recent studies have shown that the phosphatase activity of Wip1 can be suppressed by specific inhibitors, including arsenic trioxide (As₂O₃) and CCT007093 (CCT; 22, 23). Like Wip1 knockdown, inhibition of Wip1 by arsenic trioxide or CCT augmented DDR signaling, as judged by cisplatin-induced phosphorylation of Smc1 (Fig. 4C). Moreover, the treatment with either arsenic trioxide or CCT led to a significant increase in cell sensitivity to cisplatin, as measured by cell viability (Fig. 4D).

In vivo tumor growth of UM-SCC-11B cells is impaired by Wip1 knockdown

Implantation of SCC cells, including UM-SCC-11B cells, leads to formation of subcutaneous tumors in nude mice. Interestingly, UM-SCC-11B cells harboring knockdown of Wip1 expression exhibited reduced potential of tumor formation compared with the parental UM-SCC-11B cells (Fig. 5A). Tumors were excised and weighted at the end of the experiment, and Wip1 knockdown consistently





Figure 3. p53-independent expression of Wip1. HaCaT, UM-SCC-11B, and UM-SCC-38 cells were treated with cisplatin (16.7 μmol/L) for 12 hours and then analyzed by immunoblotting for expression of p53, Wip1, β-actin, and phosphorylation of Chk2.

Figure 4. Wip1 knockdown or inhibition enhances cisplatin sensitivity. **A**, UM-SCC-11B cells with control nontargeting shRNA (ctr) or Wip1 shRNA (#1 and #2) were treated with cisplatin (16.7 $\mu\text{mol/L}$) and analyzed by immunoblotting. **B**, UM-SCC-11B cells with control nontargeting shRNA or Wip1 shRNA were incubated with cisplatin at various concentrations for 4 days (as in Fig. 2A). Cell viability was determined as described in Materials and Methods. **C**, UM-SCC-11B cells were treated with cisplatin, CCT, and As_2O_3 as indicated, and analyzed by immunoblotting. **D**, cells in C were incubated with cisplatin at various concentrations for 4 days (as in Fig. 2A). Cell viability was determined as described in Materials and Methods.



reduced the tumor size by more than one-half (Fig. 5B). Our results suggest a partial addiction of these cells to Wip1 upregulation during tumorigenesis.

In vivo inhibition of Wip1 for cancer therapy

Prompted by our results showing that Wip1 knockdown or inhibition in cell culture sensitized UM-SCC-11B cells to cisplatin (Fig. 4), we sought to explore the potential of Wip1 inhibition for chemosensitization using the xenograft tumor model. We implanted UM-SCC-11B cells into nude mice to form tumors, and allowed tumors to reach 50 mm^3 in volume. We then administered cisplatin and/or arsenic trioxide intraperitoneally every day for 5 days. As shown in Fig. 6A, although treatment with either cisplatin or arsenic trioxide as a single therapeutic agent moderately reduced the rate of tumor growth, the combination treatment using both cisplatin and arsenic trioxide exhibited strong synergy and yielded a greatly improved treatment outcome in shrinking tumors (Fig. 6A). Moreover, the combination treatment is well tolerated as judged by the animal viability and weight (data not shown).

To confirm that the synergistic effect seen with arsenic trioxide in chemotherapy is at least partially due to Wip1 inhibition, we implanted UM-SCC-11B cells with or without Wip1 knockdown into nude mice, and conducted the above described therapeutic treatment using cisplatin. Interestingly, Wip1 knockdown also sensitized the cells to cisplatin as judged by decreased tumor weight (Fig. 6B). The enhanced tumor response to cisplatin observed with Wip1 knockdown is seemingly less profound than that seen with arsenic trioxide treatment, which may reflect the fact that only a partial knockdown of Wip1 expression was achieved. However, it should be noted that arsenic triox-

ide can simultaneously target other cellular pathways that contribute to cisplatin sensitization (24). Finally, we examined the effect of CCT for chemosensitization using the xenograft tumor model. Unfortunately, in our experiments, the use of CCT was limited to low concentrations because of animal lethality, suggesting very limited therapeutic window using this inhibitor. Nevertheless, like arsenic trioxide or Wip1 knockdown, the use of CCT also improved the efficacy of cisplatin (Fig. 6C).

Discussion

Like other forms of radiotherapy or chemotherapy, administration of cisplatin causes DNA damage and activates the cellular DDR pathway. In this study, we report that in some oral/laryngeal SCC cell lines, expression of several DDR factors, including ATM, Mre11, and H2AX, is significantly reduced. We showed that DDR signaling is partially defective in these cells, in correlation with chemoresistance to cisplatin. These findings are in line with several previous studies in head and neck cancer. For example, Parikh and colleagues have previously shown that partial loss of the chromosome 11q21–23 region that harbors Mre11, ATM, and H2AX genes frequently occurs in oral SCCs (25). Although the sensitivity of these cells to cisplatin was not examined, the authors reported that these cells exhibit decreased sensitivity to ionizing radiation in clonogenic survival assays (25). Moreover, independent studies discovered reduced ATM expression in a portion of head and neck cancer cases, in correlation with more aggressive clinicopathologic features (26, 27). Thus, although ATM deficiency has been shown to cause hypersensitivity to DNA damage, as characterized in ataxia telangiectasia cells (4), our study is consistent with a number of others in patients and




Figure 5. Wip1 knockdown reduces tumor growth *in vivo*. As described in Materials and Methods, UM-SCC-11B cells with control (ctr) shRNA or Wip1 shRNA were implanted into nude mice to form xenograft tumors. A, the volume of tumors was determined as described in Materials and Methods. B, at the end of the experiment, tumors were excised and weighed. Statistical significance was determined by Student *t* test ($N = 5$ per group).

animal models indicating that loss of ATM correlates with resistance to chemotherapy and poor patient survival (25, 28–32). It is plausible that ATM can differentially affect how tumors respond to chemotherapy depending on their genetic background, such as p53 status (28).

In the study by Parikh and colleagues, it has also been suggested that oral SCC cells with reduced expression of ATM, Mre11, and H2AX are deficient in DNA repair, based on the observation that these cells, collectively, exhibit elevated levels of chromosomal abnormalities (25). In the present study, we directly measured the repair efficiency in SCC cells treated with cisplatin using a modified comet assay that quantifies the presence of DNA cross-link. Interestingly, no DNA repair deficiency was detected in cells with reduced ATM, Mre11, and H2AX expression. On one hand, this finding is consistent with the fact that these cells are more resistant to cisplatin; but on the other hand, it is surprising as ATM, Mre11, and H2AX are important DDR proteins that contribute to DNA repair directly or indirectly through checkpoint activation. We speculate that this discrepancy could be because of 2 reasons: (i) redundant pathways, especially ATR-dependent signaling cascades, may compensate

the loss of the ATM-dependent pathway and sustain the checkpoint and repair functions; and (ii) key repair genes involved in NER or other repair mechanisms could be increased to allow cell survival after cisplatin treatment. Further clarifications of these aspects are potentially important as these efforts may reveal new drug targeting strategies that exploit the differential requirement of certain DDR pathways in normal and cancer cells to selectively sensitize the cancer cells to chemotherapy.

In addition to the reduced expression of ATM, Mre11, and H2AX, we discovered in the cisplatin-resistant SCC-11B and -38 cells simultaneous upregulation of Wip1. Wip1 is a homeostatic regulator of the DDR that dephosphorylates and deactivates numerous DDR factors of the ATM-dependent signaling pathway (13). Therefore, Wip1 upregulation in oral cancer cells indicates an effective mechanism to modulate DDR signaling. Wip1 was originally defined as a p53 substrate gene whose expression is induced by DNA damage in a p53-dependent manner (20). However, in UM-SCC-11B and -38 cells, we found that expression of Wip1 is neither induced by DNA damage nor dependent on p53. Thus, the elevated and constitutive expression of Wip1 in oral SCCs is attributed to other mechanisms. Interestingly, several recent studies in breast and lung cancer cells also suggested p53-independent upregulation of Wip1 expression (33–35). Clearly, the underlying mechanism of this regulation and its involvement in tumorigenesis should be investigated in the future.

We then sought to determine the functional relevance of Wip1 upregulation in oral/laryngeal SCC cells. Wip1 knockdown reduced *in vivo* tumor growth of UM-SCC-11B cell, suggesting a partial addiction of these tumor cells to Wip1 upregulation. To our knowledge, this is the first evidence that functionally characterizes an involvement of Wip1 in head and neck cancer tumorigenesis. Importantly, Wip1 knockdown enhanced ATM-dependent signaling pathway and rendered cells more sensitive to cisplatin treatment. These results suggest a therapeutic potential of Wip1 targeting in conjunction with cisplatin treatment in oral SCCs that are deficient in ATM-dependent DDR signaling pathway and resistant to cisplatin. Notably, the increased cisplatin-sensitivity resulted from Wip1 depletion or inhibition is clearly independent of p53, as UM-SCC-11B cells harbor a mutant p53 whose expression is completely suppressed. This is a surprising finding as the current understanding of the role of Wip1 in cancer progression and treatment is largely centered at its connection with p53. It has been shown in the normal cellular context that Wip1 expression is induced by p53, which is itself a key substrate of Wip1-mediated dephosphorylation and deactivation. Breast tumors with Wip1 overexpression rarely contain mutations in the p53 gene, suggesting that Wip1 may promote tumorigenesis largely through p53 inhibition (13). Moreover, several recent studies have suggested that Wip1 inactivation sensitized cancer cells to chemotherapy through p53-dependent




Figure 6. Wip1 inhibition enhances tumor response to cisplatin *in vivo*. **A**, UM-SCC-11B cells were implanted into nude mice to form tumors. As described in Materials and Methods, mice were then treated with As₂O₃ and cisplatin with 5 daily injections as indicated. Tumor volume was measured, and tumors were excised and weighed. Statistical significance was determined by Student *t* test ($N \geq 4$ per group). **B**, UM-SCC-11B cells with control (ctr) shRNA or Wip1 shRNA were implanted into nude mice to form xenograft tumors. Once the tumor reached 50 mm³ in volume, the mouse was then treated with cisplatin as in **A**, and tumor weight was determined. Statistical significance was determined by Student *t* test ($N = 4$ per group). **C**, as in **A** and **B**, UM-SCC-11B cells were implanted into nude mice, which were then treated with cisplatin alone (control) or cisplatin with CCT. Tumor weight was measured. Statistical significance was determined by Student *t* test ($N = 5$ per group).

apoptosis pathways (36–38). It has also been shown that downregulation of Wip1 enhanced chemosensitivity only in tumor cells with wt-p53, whereas, in comparison, Wip1 downregulation was completely ineffective in p53-deficient tumor cells (39). Thus, our results extend the current knowledge about the role of Wip1 in cancer progression and therapy, and strongly argue for further examination into the therapeutic potential of Wip1 targeting in p53-negative tumors. On the basis of these results, we propose an involvement of a p53-independent cell death pathway(s) that accounts for the tumor response to cisplatin, whereas activation of this pathway is negatively regulated by Wip1. Our results suggest that p53 status does not adequately determine the therapeutic potential of Wip1 targeting, and p53-dependent apoptosis alone may not serve as an exclusive readout for the efficacy of chemotherapy. This notion is in line with earlier findings showing that the wild-type status of p53 is not positively correlated or even negatively correlated with chemosensitivity in oral SCCs (21, 40).

Recent studies have identified several chemical inhibitors of Wip1, including arsenic trioxide (As₂O₃) and CCT007093 (22, 23). Historically described in traditional Chinese medicine, arsenic trioxide has been shown to possess anticancer activity, and approved by the FDA for the treatment of acute myeloid leukemia (41). The potential use of arsenic trioxide in brain, breast, ovarian, prostate, and many other types of cancers, either as a monotherapeutic agent or in combination with other anticancer drugs, has been increasingly implicated (reviewed in

refs. 24, 42). A recent study discovered that arsenic trioxide exerts its antiproliferative activity at least partially through Wip1 inhibition (22). CCT was recently identified as a potent inhibitor of Wip1 that selectively induces cell death in human breast cancer cells with Wip1 overexpression (23). In this study, we directly evaluate the therapeutic potential of these Wip1 inhibitors as conjunctive treatments with cisplatin. Excitingly, our study showed that both arsenic trioxide and CCT exhibited strong synergy with cisplatin in oral SCCs. In cell culture, the combinatorial treatments led to elevated DDR signaling and decreased cell viability compared with treatment with cisplatin alone; and in xenograft tumor models, the combinatorial treatments more effectively shrank the tumor. The use of CCT exhibited certain toxicity to the animal, which limits the therapeutic potential for this inhibitor in its current form. In comparison, the combination treatment using arsenic trioxide and cisplatin did not cause more animal lethality or weight-loss in host mice compared with treatment with cisplatin alone, suggesting good drug tolerance. The effect of CCT and arsenic oxide is conferred largely through Wip1 inhibition because: (i) CCT and arsenic oxide were shown to inhibit Wip1 (22, 23); (ii) both CCT and arsenic oxide enhanced DNA damage signaling, consistent with their role in inhibiting Wip1; (iii) CCT and arsenic oxide-induced effects are similar to that observed with Wip1 knockdown. Our results thus validate Wip1 inhibition as an attractive strategy to confer cisplatin sensitization in oral SCCs, especially those with deficient DDR to cisplatin. This

notion shall be further explored in both preclinical and clinical arenas.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: G.G. Oakley, A. Peng
Development of methodology: L. Wang, A.J. Mosel, A. Peng
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Wang, A.J. Mosel, A. Peng
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L. Wang, A.J. Mosel, G.G. Oakley, A. Peng
Writing, review, and/or revision of the manuscript: L. Wang, A. Peng
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.J. Mosel, A. Peng
Study supervision: G.G. Oakley, A. Peng

References

- Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. *Oncogene* 2012;31:1869–83.
- Caponigro F, Milano A, Basile M, Ionna F, Iaffaioli RV. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents. *Curr Opin Oncol* 2006;18:247–52.
- Zhou BB, Anderson HJ, Roberge M. Targeting DNA checkpoint kinases in cancer therapy. *Cancer Biol Ther* 2003;2:S16–22.
- Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. *Nat Rev Cancer* 2003;3:155–68.
- Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. *EMBO J* 2003;22:5612–21.
- Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD. The Mre11 complex is required for ATM activation and the G₂/M checkpoint. *EMBO J* 2003;22:6610–20.
- Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. *Science* 2003;300:1542–8.
- Kumagai A, Lee J, Yoo HY, Dunphy WG. TopBP1 activates the ATR-ATRIP complex. *Cell* 2006;124:943–55.
- Prendergast AM, Cruet-Hennequart S, Shaw G, Barry FP, Carty MP. Activation of DNA damage response pathways in human mesenchymal stem cells exposed to cisplatin or gamma-irradiation. *Cell Cycle* 2011;10:3768–77.
- Pabla N, Ma Z, McIlhatton MA, Fishel R, Dong Z. hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. *J Biol Chem* 2011;286:10411–8.
- Liang X, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ. The role of wild-type p53 in cisplatin-induced Chk2 phosphorylation and the inhibition of platinum resistance with a Chk2 inhibitor. *Chemother Res Pract* 2011;2011:715469.
- Peng A, Maller JL. Serine/threonine protein phosphatases in the DNA damage response and cancer. *Oncogene* 2010;29:5977–88.
- Lu XB, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. *Cancer Metastasis Rev* 2008;27:123–35.
- Le Guezennec X, Bulavin DV. WIP1 phosphatase at the crossroads of cancer and aging. *Trends Biochem Sci* 2010;35:109–14.
- Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. *Head Neck* 2010;32:417–26.
- Manthey KC, Glanzer JG, Dimitrova DD, Oakley GG. Hyperphosphorylation of replication protein a in cisplatin-resistant and -sensitive head and neck squamous cell carcinoma cell lines. *Head Neck* 2010;32:636–45.
- Peng A, Wang L, Fisher LA. Greatwall and Polo-like kinase 1 coordinate to promote checkpoint recovery. *J Biol Chem* 2011;286:28996–9004.
- Wang L, Fisher LA, Wahl JK 3rd, Peng A. Monoclonal antibodies against Xenopus greatwall kinase. *Hybridoma* 2011;30:469–74.
- Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. *Methods Mol Med* 1999;28:143–54.
- Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. *Proc Natl Acad Sci U S A* 1997;94:6048–53.
- Bradford CR, Zhu S, Ogawa H, Ubell M, Narayan A, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. *Head Neck* 2003;25:654–61.
- Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, et al. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. *J Biol Chem* 2008;283:18969–79.
- Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, Boxall K, et al. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. *Oncogene* 2008;27:1036–44.
- Platanias LC. Biological responses to arsenic compounds. *J Biol Chem* 2009;284:18583–7.
- Parikh RA, White JS, Huang X, Schoppa DW, Baysal BE, Baskaran R, et al. Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma. *Genes Chromosomes Cancer* 2007;46:761–75.
- He Y, Chen Q, Li B. ATM in oral carcinogenesis: association with clinicopathological features. *J Cancer Res Clin Oncol* 2008;134:1013–20.
- Lee KW, Tsai YS, Chiang FY, Huang JL, Ho KY, Yang YH, et al. Lower ataxia telangiectasia mutated (ATM) mRNA expression is correlated with poor outcome of laryngeal and pharyngeal cancer patients. *Ann Oncol* 2011;22:1088–93.
- Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. *Genes Dev* 2009;23:1895–909.
- Gumy-Pause F, Wacker P, Sappino AP. ATM gene and lymphoid malignancies. *Leukemia* 2004;18:238–42.
- Haidar MA, Kantarjian H, Manshour T, Chang CY, O'Brien S, Freireich E, et al. ATM gene deletion in patients with adult acute lymphoblastic leukemia. *Cancer* 2000;88:1057–62.
- Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. *J Clin Oncol* 2007;25:5448–57.
- Ripolles L, Ortega M, Ortuno F, Gonzalez A, Losada J, Ojanguren J, et al. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. *Cancer Genet Cytogenet* 2006;171:57–64.

Acknowledgments

The authors thank Dr. Thomas Carey (University of Michigan) for providing cell lines and Drs. Richard MacDonald and Thomas Petro for critically reading the manuscript.

Grant Support

This project was supported by Grant Number 5P20GM103489 from the National Center for Research Resources, a component of the NIH, and an American Cancer Society grant (RSG-10-031-01-CCG, G.G. Oakley).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 3, 2012; revised August 16, 2012; accepted August 30, 2012; published OnlineFirst September 12, 2012.

33. Park JY, Song JY, Kim HM, Han HS, Seol HS, Jang SJ, et al. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors. *Int J Biochem Cell Biol* 2012;44:896–904.
34. Lowe JM, Cha H, Yang Q, Fornace AJ Jr. Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase. *J Biol Chem* 2010;285:5249–57.
35. Han HS, Yu E, Song JY, Park JY, Jang SJ, Choi J. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression. *Mol Cancer Res* 2009;7:713–23.
36. Yagi H, Chuman Y, Kozakai Y, Imagawa T, Takahashi Y, Yoshimura F, et al. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. *Bioorg Med Chem Lett* 2012;22:729–32.
37. Ali AY, Abedini MR, Tsang BK. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. *Oncogene* 2011;31:2175–86.
38. Kong W, Jiang X, Mercer WE. Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. *Cancer Biol Ther* 2009;8:555–63.
39. Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV, et al. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. *Proc Natl Acad Sci U S A* 2012;109:E68–75.
40. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. *Mol Cancer Ther* 2005;4:1096–104.
41. Verstovsek S, Giles F, Quintas-Cardama A, Perez N, Ravandi-Kashani F, Beran M, et al. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? *Hematol oncol* 2006;24:181–8.
42. Emadi A, Gore SD. Arsenic trioxide—an old drug rediscovered. *Blood Rev* 2010;24:191–9.

Molecular Cancer Therapeutics

Deficient DNA Damage Signaling Leads to Chemoresistance to Cisplatin in Oral Cancer

Ling Wang, Adam J. Mosel, Gregory G. Oakley, et al.

Mol Cancer Ther 2012;11:2401-2409. Published OnlineFirst September 12, 2012.

Updated version Access the most recent version of this article at:
doi:[10.1158/1535-7163.MCT-12-0448](https://doi.org/10.1158/1535-7163.MCT-12-0448)

Cited articles This article cites 41 articles, 14 of which you can access for free at:
<http://mct.aacrjournals.org/content/11/11/2401.full#ref-list-1>

Citing articles This article has been cited by 3 HighWire-hosted articles. Access the articles at:
<http://mct.aacrjournals.org/content/11/11/2401.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/11/11/2401>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.